A Pharmaceutical Strategy that benefits EU citizens, protects healthcare systems and fosters EU competitiveness
AESGP reaction to European Commission’s Communication on the EU Pharmaceutical Strategy
AESGP welcomes the European Commission’s Communication proposing a patient-centred Pharmaceutical Strategy ensuring the quality and safety of medicines, while boosting the sector’s global competitiveness. This holistic strategy is much appreciated at a time where the world struggles amidst the COVID-19 pandemic. The global public health and economic situation has further highlighted the need for greater resilience of supply chains and health systems, and for global crises preparedness.
AESGP is committed to actively contribute to the development and implementation of a EU pharmaceutical strategy that
- considers the value of self-care pharmaceutical products
- fosters EU competitiveness and attracts investment
- can enable digital transformation
- balances environment, sustainability and healthcare needs
- can enhance smart regulation and regulatory efficiency to benefit access
- can address shortages with risk-balanced and proportional measures
AESGP is looking forward to the dialogue with the Commission, European Parliament, Member States and European Medicines Regulators on the proposed actions, in implementing an ambitious Pharmaceutical Strategy that serves all citizens, while addressing current challenges with science-based, risk-balanced and proportional measures. AESGP is committed to actively contribute to the development and implementation of a EU pharmaceutical policy that ensures the sustainability of health systems, respecting environmental concerns, and that is able to foster a successful industrial sector in Europe.
Please see the full reaction of AESGP to the European Commission’s Communication on the EU Pharmaceutical Strategy: